| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A phase II study of carboplatin AUC-10 guided by positron emission tomography–defined metabolic response in metastatic seminoma
|
Shamash, Jonathan
|
|
2019
|
115 |
C |
p. 128-135
|
artikel
|
| 2 |
Breast cancer, placenta and pregnancy
|
Froehlich, Karolin
|
|
2019
|
115 |
C |
p. 68-78
|
artikel
|
| 3 |
Cancer taxonomy: pathology beyond pathology
|
Salto-Tellez, Manuel
|
|
2019
|
115 |
C |
p. 57-60
|
artikel
|
| 4 |
Clinical outcomes and prognostic factors in recurrent and/or metastatic head and neck cancer patients treated with chemotherapy plus cetuximab as first-line therapy in a real-world setting
|
Depenni, Roberta
|
|
2019
|
115 |
C |
p. 4-12
|
artikel
|
| 5 |
Comment on ‘Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer’—No support for de-escalation of immunotherapy
|
Georgiou, Alexandros
|
|
2019
|
115 |
C |
p. 24-26
|
artikel
|
| 6 |
Development of endocrine immune-related adverse events and improved survival in advanced melanoma patients treated with nivolumab monotherapy
|
Maeda, Takuya
|
|
2019
|
115 |
C |
p. 13-16
|
artikel
|
| 7 |
Favourable outcome of de novo advanced phases of childhood chronic myeloid leukaemia
|
Millot, Frédéric
|
|
2019
|
115 |
C |
p. 17-23
|
artikel
|
| 8 |
FOLFOX alone or combined with rilotumumab or panitumumab as first-line treatment for patients with advanced gastroesophageal adenocarcinoma (PRODIGE 17-ACCORD 20-MEGA): a randomised, open-label, three-arm phase II trial
|
Malka, David
|
|
2019
|
115 |
C |
p. 97-106
|
artikel
|
| 9 |
High-dose interleukin-2 and interferon as first-line immunotherapy for metastatic melanoma: long-term follow-up in a large unselected Danish patient cohort
|
Bastholt, Lars
|
|
2019
|
115 |
C |
p. 61-67
|
artikel
|
| 10 |
Identification of high-risk drugs related to chemotherapy-induced peripheral neuropathy in Cancer Therapy Evaluation Program–sponsored phase I trials
|
Kishimoto, Shun
|
|
2019
|
115 |
C |
p. 111-119
|
artikel
|
| 11 |
Intravenous but not intrathecal central nervous system–directed chemotherapy improves survival in patients with testicular diffuse large B-cell lymphoma
|
Mannisto, S.
|
|
2019
|
115 |
C |
p. 27-36
|
artikel
|
| 12 |
Long-term efficacy of anti-PD1 therapy in Hodgkin lymphoma with and without allogenic stem cell transplantation
|
Manson, Guillaume
|
|
2019
|
115 |
C |
p. 47-56
|
artikel
|
| 13 |
Pathologist-level classification of histopathological melanoma images with deep neural networks
|
Hekler, Achim
|
|
2019
|
115 |
C |
p. 79-83
|
artikel
|
| 14 |
Screening for brain metastases in patients with stage III non–small-cell lung cancer, magnetic resonance imaging or computed tomography? A prospective study
|
Schoenmaekers, Janna
|
|
2019
|
115 |
C |
p. 88-96
|
artikel
|
| 15 |
Secondary haemophagocytic lymphohistiocytosis due to checkpoint inhibitor therapy
|
Chin, Collin K.
|
|
2019
|
115 |
C |
p. 84-87
|
artikel
|
| 16 |
The European study on centralisation of childhood cancer treatment
|
Gatta, G.
|
|
2019
|
115 |
C |
p. 120-127
|
artikel
|
| 17 |
Three cases of immune cholangitis related to anti–programmed cell death and programmed cell death ligand agents for the treatment of non-small cell lung cancer
|
Fouchard, Maxime
|
|
2019
|
115 |
C |
p. 107-110
|
artikel
|
| 18 |
Whether vitamin D supplementation protects against colorectal cancer risk remains an open question
|
Vaughan-Shaw, P.G.
|
|
2019
|
115 |
C |
p. 1-3
|
artikel
|
| 19 |
Wilms tumour event-free and overall survival in Southern and Eastern Europe: Pooled analyses of clinical data from four childhood cancer registries (1999–2017)
|
Doganis, Dimitrios
|
|
2019
|
115 |
C |
p. 37-46
|
artikel
|
Tijdschrift beschrijving